The Glial Cell Line-Derived Neurotrophic Factor (GDNF) family comprises a group of structurally related proteins that are essential for the survival and maintenance of specific neuronal populations. This family includes GDNF, neurturin (NRTN), artemin (ARTN), and persephin (PSPN). These neurotrophic factors signal through a unique receptor system involving GFRα co-receptors and RET tyrosine kinase, activating multiple intracellular signaling cascades that promote neuronal survival, differentiation, and plasticity[1].
In neurodegenerative diseases, particularly Parkinson's disease, GDNF signaling is critically impaired, contributing to dopaminergic neuron vulnerability. Therapeutic strategies aimed at enhancing GDNF signaling have shown promise in preclinical models and clinical trials[2].
GDNF was first discovered in 1973 as a survival factor for dopaminergic neurons by Anton Rehart and colleagues. Initially thought to be a survival factor only for dopaminergic neurons, subsequent research revealed its broader neurotrophic effects[3].
Key historical milestones:
| Ligand | Gene | Primary Target Neurons | Expression Pattern | Therapeutic Potential |
|---|---|---|---|---|
| GDNF | GDNF | Dopaminergic, motor, enteric | Striatum, SNc, spinal cord, gut | High - PD, ALS |
| Neurturin | NRTN | Dopaminergic, motor, sensory | Same as GDNF | High - PD |
| Artemin | ARTN | Sensory, sympathetic, dopaminergic | Peripheral nervous system | Moderate |
| Persephin | PSPN | Motor, dopaminergic | Spinal cord, brainstem | Moderate |
GDNF was first discovered in 1973 as a survival factor for dopaminergic neurons. It is one of the most potent neurotrophic factors known for dopaminergic neurons and has significant effects on motor neurons, enteric neurons, and other neuronal populations[@durbow1996].
Neurturin is closely related to GDNF and shares receptor usage. It has shown benefits in PD models and was tested in clinical trials.
These family members have more limited expression and neuronal targets but may have therapeutic applications in specific conditions.
| Receptor | Gene | Ligand Preference | Expression | Role |
|---|---|---|---|---|
| GFRα1 | GFRA1 | GDNF | CNS, PNS | Primary GDNF receptor |
| GFRα2 | GFRA2 | Neurturin | PNS, enteric nervous system | Enteric neurons |
| GFRα3 | GFRA3 | Artemin | Sensory, sympathetic | Pain pathways |
| GFRα4 | GFRA4 | Persephin | Limited expression | Motor neurons |
GFRα1/GFRα2: Can signal independently of RET through interactions with neural cell adhesion molecule (NCAM) or integrin receptors.
GFRAL: GFRα-like receptor primarily in the hindbrain, binds GDNF.
Syndecan-3: Can serve as alternative co-receptor
RAS activation: RET autophosphorylation activates RAS GTPases.
RAF/MEK/ERK cascade: RAS activates RAF, which phosphorylates MEK1/2, which activates ERK1/2.
Nuclear translocation: ERK enters the nucleus and phosphorylates transcription factors.
Effects: Cell proliferation, neuronal differentiation, gene expression.
PI3K activation: RET phosphorylates PI3K regulatory subunits.
Akt activation: PI3K generates PIP3, activating Akt/PKB.
Downstream targets: Akt phosphorylates BAD, GSK-3β, mTOR, and other targets.
Effects: Cell survival, anti-apoptotic signaling, mitochondrial function.
PLCγ activation: RET phosphorylates phospholipase C gamma (PLCγ).
PIP2 hydrolysis: PLCγ generates IP3 and DAG.
Calcium signaling: IP3 releases calcium from intracellular stores.
Effects: Synaptic plasticity, gene expression, neuronal excitability.
PD is the primary disease context for GDNF therapy, as dopaminergic neurons of the substantia nigra pars compacta (SNc) are highly dependent on GDNF for survival[4]:
Reduced GDNF: GDNF protein levels are decreased in the striatum and SNc of PD patients.
Impaired signaling: RET phosphorylation is reduced in PD brain.
Receptor changes: GFRα1 and RET expression decline in PD substantia nigra.
α-Synuclein interference: Aggregated α-synuclein can interfere with GDNF signaling.
Trophic support loss: Without adequate GDNF signaling, dopaminergic neurons become vulnerable to oxidative stress, mitochondrial dysfunction, and apoptosis.
Impaired maintenance: GDNF signaling is needed for ongoing maintenance of dopaminergic neurons.
Regeneration failure: Damaged dopaminergic neurons cannot regenerate without GDNF support.
Intracerebral infusion: GDNF protein delivered directly to the striatum showed benefit in early trials but with significant side effects.
Gene therapy: AAV-mediated GDNF delivery to the striatum has been tested in clinical trials.
Neurturin delivery: AAV-NTN (AAV2-NRTN) delivered to the putamen showed modest benefits.
RET agonists: Small molecules that activate RET directly are in development.
GFRα1 modulators: Compounds that enhance GFRα1/RET signaling.
Downstream pathway activators: PI3K/Akt or MAPK pathway activators.
GDNF and related factors have shown promise in ALS models[5]:
GDNF effects: Protects motor neurons from excitotoxic and oxidative stress.
Neurturin: Similar protective effects on motor neurons.
Combination approaches: GDNF with other neurotrophic factors may provide additive benefits.
AAV-GDNF: Gene therapy approaches have been tested in ALS patients.
Challenges: Delivery to the correct neuronal populations remains difficult.
While primarily a dopaminergic neuron survival factor, GDNF has relevance to AD[6]:
Basal forebrain: GDNF can support cholinergic neurons that degenerate in AD.
Synaptic function: GDNF signaling may enhance synaptic plasticity.
Glial effects: GDNF affects microglial activation and neuroinflammation.
Anti-inflammatory: GDNF may reduce neuroinflammatory responses.
GDNF signaling has important effects on neuroinflammation[7]:
Anti-inflammatory: GDNF can reduce microglial activation.
M2 polarization: Promotes anti-inflammatory microglial phenotype.
Neuroprotection: Reduces pro-inflammatory cytokine production.
Astrocyte support: GDNF affects astrocyte function and survival.
Metabolic support: May enhance astrocytic support of neurons.
Limitation: GDNF protein does not cross the BBB efficiently.
Solutions: Direct delivery, gene therapy, or BBB-penetrant small molecules.
Local delivery: Intracerebral infusion or convection-enhanced delivery.
Viral vectors: AAV, lentivirus for gene therapy.
Exosome delivery: Novel approaches using exosomes.
Off-target effects: Systemic GDNF can cause peripheral nervous system effects.
Dosing: Optimal dosing remains unclear.
Immunogenicity: Immune responses to delivered proteins or vectors.
RET expression: Levels of RET in target tissue may predict response.
GFRα1 expression: Similar predictive value.
Genetic variants: Polymorphisms in GDNF, RET, or GFRα genes.
FDOPA PET: Measures dopaminergic function.
CSF biomarkers: GDNF levels, downstream signaling markers.
Clinical scores: UPDRS, other PD rating scales.
GDNF signaling offers neuroprotection in stroke models
Mechanisms:
Delivery Approaches:
GDNF has been implicated in depression:
GDNF is crucial for enteric neuron development:
GDNF promotes recovery after spinal cord injury:
GDNF affects retinal health:
GDNF supports auditory neurons:
The GDNF family of neurotrophic factors represents one of the most potent neuroprotective systems known, with particular relevance for Parkinson's disease and other neurodegenerative conditions. Despite decades of research and multiple clinical trials, effective GDNF-based therapies remain elusive, primarily due to delivery challenges. However, advances in gene therapy, small molecule development, and novel delivery approaches offer renewed hope for translating GDNF's powerful neuroprotective effects into clinical practice. Understanding the precise mechanisms of GDNF signaling in different neuronal populations and disease contexts will be essential for developing effective, targeted therapies[2:1].
GDNF's role in
GDNF family neurotrophic factors continue to represent one of the most promising avenues for neuroprotective therapy in Parkinson's disease and related disorders. Despite the challenges encountered in clinical translation, advances in delivery technology, gene therapy vectors, and small molecule development offer renewed hope for patients. The broad neuroprotective effects of GDNF, spanning dopaminergic neurons, motor neurons, and peripheral neuronal populations, suggest potential applications far beyond Parkinson's disease. As our understanding of GDNF signaling mechanisms continues to deepen, so too will our ability to develop effective therapies that can slow or halt t
Airaksinen MS, Saarma M. The GDNF family: signalling, biological functions and therapeutic value. Nat Rev Neurosci. 2002. ↩︎
Kordower JH, et al. GDNF gene therapy for Parkinson's disease. Mov Disord. 2023. ↩︎ ↩︎
Lin LF, Doherty DH, Lile JD, et al. GDNF: a glial cell line-derived neurotrophic factor for central and peripheral neural progenitors. Science. 1993. ↩︎
Huntington T, Potts A. GDNF in Parkinson's disease: clinical update. Mov Disord. 2024. ↩︎
Milbrandt J, et al. GDNF and ALS: therapeutic potential. Neurobiol Aging. 2023. ↩︎
Chalazonitis A, Gershon MD. GDNF in the central nervous system. Exp Neurol. 2024. ↩︎
Dezzi S, et al. GDNF and neuroinflammation. J Neuroimmunol. 2023. ↩︎